Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Three Commercial Batches of IC51
NCT00595465Phase 3Completed
- Sponsor
- Valneva
- Start
- Dec 2007
- Primary completion
- Feb 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE) (3 arms), sponsored by Valneva. Primary endpoint: Geometric Mean Titer for Anti-JEV Neutralizing Antibody at Day 56. Started Dec 2007; status: completed.
02
Drugs
Japanese encephalitis inactivated vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT00595465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00595465.